We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT01896869
Previous Study | Return to List | Next Study

A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer

This study has suspended participant recruitment.
(On hold during during interim analysis)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01896869
First Posted: July 11, 2013
Last Update Posted: July 19, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: December 2019
  Estimated Primary Completion Date: November 2018 (Final data collection date for primary outcome measure)